Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab.

Inclusion Criteria

• •Patient with a confirmed diagnosis of active moderate to severe HS (Hurley Score 2-3)
• •Male or Female adult patients ≥ 18 years of age at the time of data collection
• •Patient newly initiated on Secukinumab (first dose to coincide within 1 month of the signature of the informed consent)
• •Patients with a diagnosis of HS who are currently using antibiotics/ have undergone surgery or not as part of their routine clinical management are eligible for inclusion.
• •Patients with a diagnosis of HS who have a history of previous treatment with Adalimumab or any other anti-TNF agent as part of their routine clinical management or biologic naïve are eligible for inclusion.
• •Agreed to sign an informed consent to be able to fill in the questionnaires.
• •Patient's refusal to be included in the study or refusal to sign the informed consent.